



National Collaborative for Innovation in Quality Measurement

Use of Multiple Concurrent Antipsychotics in Children

Administrative Specification

Measure Description

The percentage of children 0 to 20 years of age on any antipsychotic medication for 90 days or more during the measurement year who were on two or more concurrent antipsychotic medications for 90 days or more.

Note: While a rate of zero is not expected for this measure, a lower rate indicates better performance.

Eligible Population

Product Line Medicaid

Ages 0 to 20 years by December 31 of the measurement year. Report four age stratifications.

- 0-5 years
- 6-11 years
- 12-17 years
- 18-20 years
- Total

The total is the sum of the age stratifications.

Continuous Enrollment 90 days or more.

Allowable Gap None

Benefits Medical and Pharmacy.

Event/diagnosis Children on any antipsychotic medication for 90 days or more (Table 1).

Numerator

On two or more concurrent antipsychotic medications for 90 days or more during the measurement year (Table 1).

Exclusions

None

Table 1. Antipsychotic Medications

First Generation Antipsychotic Medications	Second Generation Antipsychotic Medications
chlorpromazine hcl	aripiprazole
fluphenazine hcl	clozapine
fluphenazine decanoate	iloperidone
fluphenazine enanthate	olanzapine
haloperidol	olanzapine pamoate
haloperidol decanoate	paliperidone
haloperidol lactate	paliperidone palmitate
loxapine hcl	quetiapine fumarate
loxapine succinate	risperidone
molindone hcl	risperidone microspheres
perphenazine	ziprasidone hcl
pimozide	ziprasidone mesylate
promazine hcl	
thioridazine hcl	
thiothixene	
thiothixene hcl	
trifluoperazine hcl	
triflupromazine hcl	
Combinations	
Olanzapine-fluoxetine hcl (Symbyax)	
Perphenazine-amitriptyline hcl (Etrafon, Triavil (various))	